

Special Issue

Cancer Nanotherapy and Nanodiagnostic

Message from the Guest Editors

"Cancer Nanotherapy and Nanodiagnostic" is an interdisciplinary field where nanoscience, nanoengineering, and nanotechnology interact with the life sciences. The use of nanomaterials offers numerous advantages when compared to conventional cancer medicine, including innovative therapeutic and imaging modalities, improved pharmacokinetic and pharmacodynamic performances, enhanced tumor penetration and targeting, increased contrast efficiency and multi-spectral capabilities, possibility to develop smart delivery systems and point-of-care devices. Thanks to their multifunctional properties, nanomaterials also provide the opportunity of combining diagnosis and therapy (theranostics) in a single platform. This Special Issue of *Cancers* entitled "Cancer Nanotherapy and Nanodiagnostic" welcomes both original papers and review articles addressing recent research and novel developments in the field of nanomaterials for applications in cancer therapy and diagnostic, including their modelling, fabrication, characterization, and in vitro and in vivo applications.

Guest Editors

Dr. Stefania Biffi

Researcher, Institute of Maternal and Child Health, IRCSS Burlo Garofolo, Trieste, Italy

Prof. Dr. Matteo Calvaresi

Dipartimento di Chimica "Giacomo Ciamician", Alma Mater Studiorum—Università di Bologna, Bologna, Italy

Deadline for manuscript submissions

closed (31 July 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/116601

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)